恩格列净和阿托伐他汀连用治疗2型糖尿病并发肾病的临床研究

Clinical Study on the Combined Use of Empagliflozin and Atorvastatin in the Treatment of Type 2 Diabetes Mellitus Complicated with Nephropathy

目的针对2型糖尿病并发肾病(diabetic nephropathy,DN)患者行恩格列净与阿托伐他汀联合治疗,对治疗效果予以观察总结。方法选取2021年1-12月内蒙古自治区赤峰市医院100例DN患者为研究对象,分组依据随机数表法,观察组(恩格列净联合阿托伐他汀治疗)与对照组(单一阿托伐他汀治疗),各50例,对比患者血糖指标、肾功能指标在治疗前后的变化,评估治疗效果,随访不良反应发生率。结果治疗前两组FPG、2 hPG、HbA1c水平比较,差异无统计学意义(t=0.243、0.274、0.253,P>0.05);治疗后组间比较观察组均低于对照组,差异有统计学意义(t=18.875、19.730、12.404,P<0.05)。治疗前两组各项肾功能指标比较,差异无统计学意义(t=0.364、0.149、0.523、0.452,P>0.05);治疗后观察组BUN、Cr、β_(2)-MG、UAE均低于对照组,差异有统计学意义(t=11.927、11.087、7.780、11.839,P<0.05)。观察组总有效率为92.00%,高于对照组的76.00%,差异无统计学意义(χ^(2)=4.762,P<0.05)。两组并发症发生率比较,差异无统计学意义(χ^(2)=0.177,P>0.05)。结论恩格列净和阿托伐他汀联合应用于DN治疗,有利于提升血糖控制效果,改善肾功能,且安全有保障,疗效可靠,可予以推广。

Objective To observe and summarize the therapeutic effect of empagliflozin combined with atorvastatin in patients with type 2 diabetes mellitus complicated with nephropathy(diabetic nephropathy,DN).Methods 100 DN patients in Chifeng Hospital of Inner Mongolia Autonomous Region from January to December 2021 were selected as the study objects,and the grouping was based on the random number table method,with 50 cases in the observation group(empagliflozin combined with atorvastatin treatment)and the control group(single atorvastatin treatment).The changes of blood glucose indexes and renal function indexes of patients before and after treatment were compared.The treatment effect was evaluated and the incidence of adverse reactions was followed up.Results There was no statistically significant difference in the levels of FPG,2 hPG and HbA1c between the two groups before treatment(t=0.243,0.274,0.253,P>0.05);after treatment,the observation group was lower than the control group,and the difference was statistically significant(t=18.875,19.730,12.404,P<0.05).The differences of renal function indexes between the two groups before treatment were compared,and the difference was not statistically significant(t=0.364,0.149,0.523,0.452,P>0.05);after treatment,BUN,Cr,β_(2)-MG and UAE in the observation group were lower than those in the control group,and the difference was statistically significant(t=11.927,11.087,7.780,11.839,P<0.05).The total effective rate in the observation group was 92.00%,which was higher than 76.00%in the control group,and the difference was statistically significant(χ^(2)=4.762,P<0.05).There was no statistically significant difference in the incidence of complications between the two groups(χ^(2)=0.177,P>0.05).Conclusion The combined application of empagliflozin and atorvastatin in the treatment of DN is beneficial to improve the effect of blood glucose control and renal function,and is safe and reliable,and can be promoted.